Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation

Takashi Ogawa, Genko Oyama, Nobutaka Hattori

SUMMARY
A 42-year-old Japanese man with a history of small intestine resection and familial Mediterranean fever was referred to our hospital for a second opinion on parkinsonism. At the age of 35, the patient attended a hospital due to impaired left-hand movement and resting tremor. He was previously diagnosed with multiple system atrophy based on the lack of effectivenss of levodopa treatment. With suspicion of malabsorption due to his history of ileostomy, a levodopa challenge test with levodopa intravenous infusion was conducted, and revealed a 65% improvement in Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) with 200 mg levodopa intravenous infusion. Diagnosis of PD was made according to the diagnostic criteria of the UK Parkinson’s Disease Society Brain Bank.

TREATMENT
A transdermal rotigotine patch was selected as treatment to bypass gastrointestinal absorption of medication. We gradually increased rotigotine from 2 mg/24 hours to 16 mg/24 hours.

OUTCOME AND FOLLOW-UP
This treatment dose-dependently improved the patient’s symptoms (figure 1). Ultimately, the patient’s parkinsonism was well controlled with only rotigotine, and his MDS-UPDRS score improved from 44 to 11 points.

DISCUSSION
In the present case, levodopa responsiveness was masked by malabsorption due to a previous small intestinal operation, which was revealed by a levodopa infusion test. Subsequently, transdermal drug delivery resolved this problem.

PD can be comorbid with gastrointestinal issues, such as gastroparesis, constipation and small intestinal bacterial overgrowth, with a prevalence ranging from 3.7% to 16.7%. These comorbidities may cause malabsorption of anti-Parkinsonian medications, possibly working in combination with the intake of high-protein foods and antacids, such as proton pump inhibitors. Absorption problem may lead to motor fluctuations such as "delayed on", "wearing off" and drug failure ("no on") in advanced stages of the disease. Furthermore, malabsorption may lead to diagnostic delay or misdiagnosis in the early stages of disease.

Gastrointestinal problems can be induced by surgery such as resection of the digestive tract or a severe gastrointestinal ulcer. It is difficult to control parkinsonism in the perioperative period and other states in which intake is impaired. To date, levodopa infusion, amantadine infusion, subcutaneous administration of apomorphine and transdermal administration of rotigotine have been reported to successfully control parkinsonism in the perioperative period. In addition, liquid formulations of levodopa such as Meledopa may be an option for patients with gastrointestinal problems.

The use of a transdermal rotigotine patch is one method for avoiding absorption problems.
A transdermal rotigotine patch provides continuous delivery of dopamine agonist to the blood, bypassing gastrointestinal absorption issues. Dafotakis and colleagues reported a PD case in which the akinetic crisis was due to multiple severe esophageal fissures and ulcers. This case was ultimately improved with the use of rotigotine patches 16 mg/24 hours (total drug content: 36 mg). In conclusion, transdermal drug delivery should be considered when patients show dose failure due to malabsorption.

**Learning points**

- Drug malabsorption is an important contributing factor to motor fluctuations in Parkinson’s disease.
- Gastrointestinal problems can be induced by surgery especially in the digestive tract.
- Transdermal drugs need to be considered when patients have significant malabsorption.

**Contributors**
TO and GO drafted the manuscript. NH reviewed the manuscript and provided suggestions. All authors read and approved the final manuscript.

**Funding**
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**
None declared.

**REFERENCES**

1. Sung HY, Park JW, Kim JS. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson’s disease. *J Mov Disord* 2014;7:7–12.
2. Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson’s disease. *World J Gastroenterol* 2016;22:5742–52.
3. Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized Parkinson’s disease patient: systematic review. *Mov Disord* 2011;26:197–208.
4. Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson’s disease. *Lancet Neurol* 2015;14:625–39.
5. Stocchi F, Marconi S. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). *Clin Neuropharmacol* 2010;33:198–203.
6. Dafotakis M, Sparing R, Juzek A, et al. Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. *J Clin Neurosci* 2009;16:335–7.